Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 19.
SenoRx Announces Poster Presentation on Interim Results of the First 100 Patients in its Contura(TM) MLB Registry Study Delivered at American Society for Radiology and Oncology (ASTRO)
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
IRVINE, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- SenoRx (Nasdaq:SENO) today announced that a poster presentation summarizing clinical findings of the first 100 patients in its Contura(TM) Multi-Lumen Balloon (MLB) registry study was delivered at the Annual Meeting of the American Society for Radiology and Oncology (ASTRO) on November 3, 2009 in Chicago, Illinois.
Source: Medical News (via PRIMEZONE) - November 5, 2009 Category: Pharmaceuticals Source Type: news
SenoRx Announces Poster Presentation on Interim Results of the First 100 Patients in its Contura(TM) MLB Registry Study Delivered at American Society for Therapeutic Radiology and Oncology (ASTRO)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
IRVINE, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- SenoRx (Nasdaq:SENO) today announced that a poster presentation summarizing clinical findings of the first 100 patients in its Contura(TM) Multi-Lumen Balloon (MLB) registry study was delivered at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) on November 3, 2009 in Chicago, Illinois.
Source: Medical News (via PRIMEZONE) - November 5, 2009 Category: Pharmaceuticals Source Type: news
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical OncologyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Complete durable eradication of disease achieved in a
significant number of patients with investigational therapy for
advanced Stage III and Stage IV melanoma
WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company
developing new generation...
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials
Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Short-term hormone
therapy given prior to and during radiation treatment to
medium-risk prostate cancer patients increases their chance of
living longer, compared to those who receive radiation...
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials
IMS Health Nears LBO DealEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
IMS Health is nearing a deal to sell itself to private-equity firm TPG and the Canada Pension Plan in a deal that could have a value of almost $4 billion.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov. 5 (HSMN NewsFeed) -- Amgen (Nasdaq: AMGN ) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination ... Biopharmaceuticals, OncologyAmgen, Vectibix, panitumumab, metastatic colorectal cancer
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
Chelation Therapy Drug Found Safe and Beneficial for Children With AutismEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Autism Research Institute calls for further
investigations into the use of chelation therapy for individuals
with autism
SAN DIEGO, Nov. 5 /PRNewswire-USNewswire/ -- Two studies
published by the Southwest College of Naturopathic Medicine in...
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials
New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the BloodEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers Highlight the Unique Advantages of Masimo SpCO(R) to Facilitate Early Diagnosis of Carbon Monoxide Poisoning On-the-Scene
IRVINE, Calif., Nov. 5 (HSMN NewsFeed) -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-T... Devices, MonitoringMasimo, Pulse CO-Oximetry, carbon monoxide, CO poisoning
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX (Varenicline) Compared With PlaceboEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Findings from Pfizer-Sponsored Study Presented as
Late-Breaker at American College of Chest Physicians Annual
Meeting
SAN DIEGO--(BUSINESS WIRE)--Nov 4, 2009 - New study results
showed that 42.3 percent of smokers with mild-to-moderate...
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of PirfenidoneEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BRISBANE, Calif., Nov. 5 (HSMN NewsFeed) -- InterMune, Inc. (Nasdaq: ITMN ) today announced additions to its senior leadership team to prepare for the potential commercialization of pirfenidone in the United States and Europe.
The company announced ye... Biopharmaceuticals, PersonnelInterMune, pirfenidone
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
LDR Reaches Key 24-month Milestone Since Finalizing Enrollment of its 1-Level Cervical Disc Study in the United StatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LDR Launches PMA Process with 2-year Patient Follow-up
AUSTIN, Texas, Nov. 5--(HSMN NewsFeed)--LDR, a privately held company with innovative spinal implants for both non-fusion and fusion applications, reached the critical 24-month follow-up phase for t... Devices, Orthopaedic, NeurosurgeryLDR Spine, Mobi-C, cervical artificial disc
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
ABRAXANE® Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LOS ANGELES, Nov. 5--(HSMN NewsFeed)--Abraxis BioScience, Inc. (NASDAQ:ABII ), a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug design... Biopharmaceuticals, Oncology, FDAAbraxis BioScience, ABRAXANE, pancreatic cancer, melanoma
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LOS ANGELES, Nov. 5--(HSMN NewsFeed)--Abraxis BioScience, Inc. (NASDAQ:ABII ), a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug design... Biopharmaceuticals, Oncology, FDAAbraxis BioScience, ABRAXANE, paclitaxel, pancreatic cancer, melanoma
Source: HSMN NewsFeed - November 5, 2009 Category: Pharmaceuticals Source Type: news
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
– Research Findings Include Rational Design of Mimetic
Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data
Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on
RNA Activation Research Efforts –
CAMBRIDGE,...
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials
Man Sentenced For Sale And Supply Of Controlled And Counterfeit DrugsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A 41-year-old man, Mr Harish Gami, received an eight month prison sentence suspended for two years at Aylesbury Crown Court today for the illicit sale and supply of controlled drugs as well as counterfeit and unlicensed medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) discovered more than 86,000 Valium tablets and a further 11,500 medicinal products in an undercover investigation into Gami's illegal online dealing.
Source: Pharma Industry News From Medical News Today - November 5, 2009 Category: Pharmaceuticals Tags: Litigation / Medical Malpractice Source Type: news
The Creation Of A New Niche Specialty Pharmaceutical Company Focused On Rare Diseases - With Strong Cash Flow Generation And Growth PotentialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Biovitrum and Swedish Orphan will be combined forming Swedish Orphan Biovitrum with pro forma revenues 2009 of approximately SEK 2 billion and an EBITDA margin of 15 percent. Biovitrum will pay an upfront consideration of SEK 3.5 billion (on a cash and debt free basis), to be financed by a fully guaranteed rights issue, an issue in kind and bank financing. The Transaction will be instantly accretive to earnings per share for Biovitrum's shareholders. Shared mission.
Source: Pharma Industry News From Medical News Today - November 5, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news
Catalent Pharma Solutions Enters A Strategic Alliance With Endotis PharmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
ViraCor-IBT Laboratories To Present At The American College Of Allergy, Asthma And Immunology's Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Scientists from ViraCor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year's American College of Allergy, Asthma and Immunology's Annual Scientific Meeting in Miami, Florida. Michelle Altrich, PhD, HCLD (ABB), and Michael Ling, PhD, will present data on a wide range of topics including Filaggrin, Pneumococcal Antibody Avidity, Chronic Urticaria, Drug Hypersensitivity Reactions and T-Cell Excision Circles.
Source: Pharma Industry News From Medical News Today - November 5, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news
FDA Unveils Safe Use Initiative That Targets Preventable Harm From Medication UseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.S. Food and Drug Administration announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. "Too many people suffer unnecessary injuries from avoidable medication misuse, errors and other problems. The FDA is launching the Safe Use Initiative to develop targeted solutions for reducing these injuries," said FDA Commissioner Margaret A. Hamburg, M.D.
Source: Pharma Industry News From Medical News Today - November 5, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news
Drug Company-sponsored Events For Health Professionals Fail To Disclose Financial TiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Australian reporting standards for disclosing the ties between pharmaceutical companies and health professionals are not comprehensive enough, according to an analysis in this weeks PLoS Medicine.
Source: Pharma Industry News From Medical News Today - November 5, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news
FDA Grants Orphan Drug Designation For Tnferade™Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GenVec, Inc. announced recently that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to
TNFeradeT for the treatment of pancreatic cancer.
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Micromeritics And Surface Measurement Systems Announce Global CollaborationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Particulate Systems, a brand of Micromeritics Instrument Corporation, and Surface Measurement Systems Limited are pleased to announce a Global Strategic Collaboration starting October 2009.
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Malvern Sponsors Protein Aggregation Track At PepTalk 2010Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
As well as presenting a technical paper and exhibiting from its range of Zetasizer light scattering solutions and Viscotek size exclusion chromatography systems, Malvern Instruments is sponsoring the 'Protein Aggregation' track at the next Cambridge Healthtech Institute PepTalk conference (January 11-15, 2010, San Diego, California).
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Daiichi Sankyo begins late-stage trials of flu drugEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Daiichi Sankyo, has begun a late-stage trial in Japan for the influenza treatment laninamivir, a drug that aims to prevent new H1N1 flu.
Source: The Economic Times Healthcare and Biotech News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Sizing Up Campus Health CareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Growing job losses have college students scrambling for health care. But campus services and insurance plans vary widely. Here's what to watch for.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
DSM Pharmaceutical Products Forms Manufacturing Alliance With GalenixEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
DSM Pharmaceutical Products recently announced that it has made a manufacturing alliance with Galenix, Saint Jean D'Illac, France, where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Democrats Eye Saturday Health VoteEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democratic leaders are pushing for a Saturday vote on their health-care bill, but they are struggling to win over shaky rank-and-file members who could hold up its passage.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Malvern's Chemical Imaging System Helps Solve A Major Challenge In Paediatric Drug DevelopmentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers at the Institute of Pharmaceutics and Biopharmaceutics at the University of Düsseldorf in Germany have taken delivery of a Near Infrared Chemical Imaging
(NIR-CI) system from Malvern Instruments (Malvern, UK).
Source: Pharmaceutical Online News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Democrats Eye Saturday Health VoteEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democratic leaders are pushing for a Saturday vote on their health-care bill, but they are struggling to win over shaky rank-and-file members who could hold up its passage.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Sizing Up Campus Health CareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Growing job losses in the workplace are having an impact on college campuses, as students increasingly are forced to scramble for health care. But campus health services and insurance plans vary widely. Here's what to watch for.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Democrats Eye Vote on HealthEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democratic leaders are pushing for a Saturday vote on their health-care bill, but they are struggling to win over shaky rank-and-file members who could hold up its passage.
Source: WSJ.com: Health - November 5, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Ultrasis posts first pre-tax profitEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The interactive healthcare software maker reports a 59% increase in revenues to £4.2m due to gains from its computer program designed to treat depression
Source: FT.com - Drugs and Healthcare - November 5, 2009 Category: Pharmaceuticals Source Type: news
New Merck Begins OperationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.
Source: World Pharma News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.
Source: Amgen News Service - November 5, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations
Cut Out, Chemically Bombarded and Burned to Death; This Book Provides Oxygen to an Otherwise Airless TimeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHICAGO, Nov. 4, 2009 (GLOBE NEWSWIRE) -- There are 50,000 women noted in Marquis' "Who's Who of American Women." Statistics show that 6,250 of these women will get breast cancer. One of these women is Suzanne Zaccone, one of America's most influential entrepreneurs.
Source: Medical News (via PRIMEZONE) - November 4, 2009 Category: Pharmaceuticals Source Type: news
TearLab Corporation to Release Q3-09 Financial Results on November 12 -- Conference Call to FollowEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN DIEGO, Nov. 4, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR)(TSX:TLB) expects to announce its third quarter 2009 financial results after the market closes on Thursday, November 12, 2009. OccuLogix is pleased to invite all interested parties to participate in a conference call during which the financial results will be discussed. The call will be held on November 12, at 4:30p.m. Eastern Time at 800-311-0799 (within the United States and Canada).
Source: Medical News (via PRIMEZONE) - November 4, 2009 Category: Pharmaceuticals Source Type: news
Merck Seeks Biotech AcquisitionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck's CEO said the drug maker is looking to buy biotechnology companies in the "single-digit" billions of dollars.
Source: WSJ.com: Health - November 4, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Vital Images Announces Third Quarter ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MINNEAPOLIS, Nov. 4, 2009 (GLOBE NEWSWIRE) -- Vital Images, Inc. (Nasdaq:VTAL), a leading provider of advanced visualization and analysis solutions, today reported financial results for the third quarter ended September 30, 2009. Third quarter revenue was $14.3 million, compared to $17.7 million for the third quarter of 2008. Third quarter net loss was $750,000, or $(0.05) per diluted share, compared to a net loss of $243,000, or $(0.02) per diluted share, for the third quarter of 2008.
Source: Medical News (via PRIMEZONE) - November 4, 2009 Category: Pharmaceuticals Source Type: news
Merck Seeks Biotech AcquisitionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck's CEO said the drug maker is looking to buy biotechnology companies in the "single-digit" billions of dollars.
Source: WSJ.com: Health - November 4, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SALT LAKE CITY, Nov. 4, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., is scheduled to present an overview of the Company at the Lazard Capital Markets Sixth Annual Healthcare Conference, at 9:30 a.m. Eastern on November 18, 2009, at the St. Regis Hotel in New York City.
Source: Medical News (via PRIMEZONE) - November 4, 2009 Category: Pharmaceuticals Source Type: news
OraSure Announces 2009 Third Quarter Financial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BETHLEHEM, Pa., Nov. 4, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $21.6 million for the three months ended September 30, 2009, compared to $16.9 million recorded for the three months ended September 30, 2008.
Source: Medical News (via PRIMEZONE) - November 4, 2009 Category: Pharmaceuticals Source Type: news
Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Includes Clinical Data for XL147, XL765 and XL139
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 4, 2009 -
Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen
abstracts related to the company's development candidates have been
accepted...
Source: Drugs.com - Clinical Trials - November 4, 2009 Category: Pharmaceuticals Source Type: clinical trials
Roll up for Japan's medical mystery tourEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
With a smaller slice of a shrinking domestic pie, Japanese pharmaceutical companies have had to take the fight abroad. The country's track record outside manufacturing does not bode well, but it is too soon to dismiss the industry, writes David Pilling
Source: FT.com - Drugs and Healthcare - November 4, 2009 Category: Pharmaceuticals Source Type: news
Concerta in the Classroom: New Data on Attention in Children With ADHDEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today
show that CONCERTA® (OROS® methylphenidate HCl
Extended-Release Tablets CII) is the only stimulant medication with
data that demonstrate a significant treatment effect on...
Source: Drugs.com - Clinical Trials - November 4, 2009 Category: Pharmaceuticals Source Type: clinical trials
New Data on Attention in Children with ADHDEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LAS VEGAS, Nov. 4, 2009 – New findings presented today
show that CONCERTA® (OROS® methylphenidate HCl
Extended-Release Tablets CII) is the only stimulant medication with
data that demonstrate a significant treatment effect on attention
at...
Source: Drugs.com - Clinical Trials - November 4, 2009 Category: Pharmaceuticals Source Type: clinical trials
Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal StudiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data Supports Compound's Potential as a Countermeasure for
Chlorine Gas Exposure
MISSION VIEJO, Calif.--(BUSINESS WIRE)--Nov 4, 2009 - Aeolus
Pharmaceuticals, Inc. (OTCBB: AOLS) reported that researchers from
National Jewish Health and McGill...
Source: Drugs.com - Clinical Trials - November 4, 2009 Category: Pharmaceuticals Source Type: clinical trials
Promedior Announces Publication of Preclinical Studies in Science Translational Medicine Demonstrating that hSAP Inhibits Kidney FibrosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MALVERN, Pa.--(BUSINESS WIRE)--Nov 4, 2009 - Promedior, Inc., a
leader in the development of novel therapeutics for the treatment
of fibrotic diseases and tissue remodeling, announced today the
publication of results from preclinical studies...
Source: Drugs.com - Clinical Trials - November 4, 2009 Category: Pharmaceuticals Source Type: clinical trials
Merck Offers Savings TargetEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck said it expects annual savings of $3.5 billion beyond 2011 after the completion Tuesday of its acquisition of fellow drug maker Schering-Plough.
Source: WSJ.com: Health - November 4, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
